Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California News Observer.
Press releases published on July 11, 2025

DEADLINE ALERT for RDDT, HIMS, IRBT, and CNC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed …

Create Source Media releases 'Confío Celebro,' a global inspirational Spanish song / canción inspiradora
“Create Source Media amplifies hope worldwide with powerful new inspirational Global Spanish anthem” LOS ANGELAS, CA, UNITED STATES, July 10, 2025 /EINPresswire.com/ -- Create Source Media announces “Confío Celebro,” releasing August 8, 2025 via The …

Music, Memories and Miracles: 28th Annual Stars and Stripes Raises $6M for Kids’ Charities
OneRepublic, Little Big Town …

CAI Community Launches AlgoFusion 5.0 Led by Alaric Bennett
Los Angeles, CA, July 11, 2025 (GLOBE NEWSWIRE) -- CAI Community, the investor-focused learning platform established by hedge fund veteran Alaric Bennett, has officially announced the release of AlgoFusion 5.0, a major update to its proprietary trading …

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today published a new peer-reviewed study in Neuron, a Cell Press …

Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal securities laws by making false or misleading statements …

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
– Absence of neurotoxicity of any grade in low-volume disease to-date – – On track for first Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – – Potential future indication expansion planned …

XPLR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that XPLR Infrastructure, LP f/k/a NextEra Energy Partners, LP Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – XIFR
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman …

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation (CNC) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman …

Johnson Fistel Begins Investigation on Behalf of BellRing Brands, Inc. (BRBR) Shareholders
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, is investigating whether BellRing Brands, Inc. (NYSE: BRBR), or any of its executive officers, violated securities laws by misrepresenting or failing to timely …

Johnson Fistel Begins Investigation on Behalf of KinderCare Learning Companies, Inc. (KLC) Shareholders
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether KinderCare Learning Companies, Inc. (NYSE: KLC), or any of its executive officers, violated securities laws by misrepresenting or failing …

ServiceTitan to Host Investor Session at Pantheon 2025
LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- ServiceTitan (Nasdaq: TTAN), the software platform that powers the trades, today announced that it will host an investor session at Pantheon 2025, the Company’s annual user conference in Anaheim, CA. The in- …

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and …

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a …

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million non-dilutive …

Heartflow Plaque Analysis Awarded First Coverage Recommendation by Radiology Benefits Manager
MOUNTAIN VIEW, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit …

Ugh, As If! The Bratz Betties Just Went Full-On Clueless in This Totally Major Collector Collab
LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Bratz®, the on-trend lifestyle and fashion doll brand from MGA Entertainment (MGA), announced today the launch of its Bratz x Clueless Collector dolls in collaboration with Paramount Consumer Products, a …

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy FDA …